# EDGAR Filing Document

**Accession Number:** 0001798550
**File Stem:** 0001193125-23-024216
**Filing Date:** 2023-2
**Character Count:** 14708
**Document Hash:** c3e0a0fb130e83d1d03c186ee10b75d8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-024216.hdr.sgml**: 20230203

**ACCESSION NUMBER**: 0001193125-23-024216

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230203

**DATE AS OF CHANGE**: 20230203

**GROUP MEMBERS**: SUMITOMO PHARMA CO., LTD. (FORMERLY KNOWN AS SUMITOMO DAINIPPON PHARMA CO., LTD.)

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Roivant Sciences Ltd.
- **CENTRAL INDEX KEY:** 0001635088
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 981173944
- **STATE OF INCORPORATION:** D0
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93291
- **FILM NUMBER:** 23586468

**BUSINESS ADDRESS:**
- **STREET 1:** CLARENDON HOUSE, 2 CHURCH STREET
- **CITY:** HAMILTON HM11
- **STATE:** D0
- **ZIP:** HM11
- **BUSINESS PHONE:** 441-295-5950

**MAIL ADDRESS:**
- **STREET 1:** CLARENDON HOUSE
- **STREET 2:** 2 CHURCH STREET
- **CITY:** HAMILTON
- **STATE:** D0
- **ZIP:** HM11
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sumitomo Chemical Co., Ltd.
- **CENTRAL INDEX KEY:** 0001798550
- **IRS NUMBER:** 980339148
- **STATE OF INCORPORATION:** M0
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 7-1, NIHONBASHI 2-CHOME
- **STREET 2:** CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-6020
- **BUSINESS PHONE:** 813-5201-0222

**MAIL ADDRESS:**
- **STREET 1:** 7-1, NIHONBASHI 2-CHOME
- **STREET 2:** CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-6020

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**SCHEDULE 13G** 

**Under the Securities Exchange Act of 1934** 

**(Amendment No. 1)** 

------

## Roivant Sciences Ltd.
**(Name of Issuer)** 

**Common Shares, par value $0.0000000341740141 per share** 

**(Title of Class of Securities)** 

**G76279101** 

**(CUSIP Number)** 

**December 31, 2022** 

**(Date of Event Which Requires Filing of this Statement)** 

------

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;NAMES OF REPORTING PERSONS<br>&nbsp;&nbsp;&nbsp;&nbsp;Sumitomo Chemical Co., Ltd. | &nbsp;&nbsp;&nbsp;&nbsp;NAMES OF REPORTING PERSONS<br>&nbsp;&nbsp;&nbsp;&nbsp;Sumitomo Chemical Co., Ltd. | &nbsp;&nbsp;&nbsp;&nbsp;NAMES OF REPORTING PERSONS<br>&nbsp;&nbsp;&nbsp;&nbsp;Sumitomo Chemical Co., Ltd. |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ | &nbsp;&nbsp;&nbsp;&nbsp;CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ | &nbsp;&nbsp;&nbsp;&nbsp;CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC USE ONLY | &nbsp;&nbsp;&nbsp;&nbsp;SEC USE ONLY | &nbsp;&nbsp;&nbsp;&nbsp;SEC USE ONLY |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>&nbsp;&nbsp;&nbsp;&nbsp;Japan | &nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>&nbsp;&nbsp;&nbsp;&nbsp;Japan | &nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>&nbsp;&nbsp;&nbsp;&nbsp;Japan |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 5 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE VOTING POWER<br>|
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 6 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;86,367,360 |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 7 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE DISPOSITIVE POWER<br>|
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 8 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;86,367,360 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 9 | &nbsp;&nbsp;&nbsp;&nbsp;AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>&nbsp;&nbsp;&nbsp;&nbsp;86,367,360 |
| &nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>&nbsp;&nbsp;&nbsp;&nbsp;11.91% (1) |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;TYPE OF REPORTING PERSON<br>&nbsp;&nbsp;&nbsp;&nbsp;CO |

---

(1) This calculation is based on 725,418,787 Common Shares, $0.0000000341740141 par value, of the Issuer (as
defined below), issued and outstanding as of November 10, 2022, as disclosed by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2022, as filed with the Securities and
Exchange Commission on November 14, 2022.

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;NAMES OF REPORTING PERSONS<br>&nbsp;&nbsp;&nbsp;&nbsp;Sumitomo Pharma Co., Ltd. (formerly known as Sumitomo Dainippon Pharma Co., Ltd.) |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC USE ONLY |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>&nbsp;&nbsp;&nbsp;&nbsp;Japan |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 5 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;86,367,360 |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 6 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED VOTING POWER<br>|
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 7 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;86,367,360 |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 8 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED DISPOSITIVE POWER<br>|

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 9 | &nbsp;&nbsp;&nbsp;&nbsp;AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>&nbsp;&nbsp;&nbsp;&nbsp;86,367,360 |
| &nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>&nbsp;&nbsp;&nbsp;&nbsp;11.91% (1) |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;TYPE OF REPORTING PERSON<br>&nbsp;&nbsp;&nbsp;&nbsp;CO |

---

(1) This calculation is based on 725,418,787 Common Shares, $0.0000000341740141 par value, of the Issuer (as
defined below), issued and outstanding as of November 10, 2022, as disclosed by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2022, as filed with the Securities and
Exchange Commission on November 14, 2022.

------

---

| | |
|:---|:---|
| **Item 1(a).** | **Name of Issuer:**  |

---

Roivant Sciences Ltd. (the "Issuer").

---

| | |
|:---|:---|
| **Item 1(b).** | **Address of Issuer's Principal Executive Offices:**  |

---

Roivant Sciences Ltd.

7th Floor

50 Broadway

London SW1H 0DB

United Kingdom

---

| | |
|:---|:---|
| **Item 2(a).** | **Name of Person Filing:**  |

---

Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical").

Sumitomo Pharma Co., Ltd. (formerly known as Sumitomo Dainippon Pharma Co., Ltd.) ("Sumitomo Pharma").

(Each a "Reporting Person," and collectively, the "Reporting Persons").

---

| | |
|:---|:---|
| **Item 2(b).** | **Address of Principal Business Office or, if None, Residence:**  |

---

Sumitomo Chemical:

7-1, Nihonbashi 2-chome

Chuo-ku, Tokyo

103-6020, Japan

Sumitomo Pharma:

6-8 Doshomachi 2-chome

Chuo-ku, Osaka

541-0045, Japan

---

| | |
|:---|:---|
| **Item 2(c).** | **Citizenship:**  |

---

See Row 4 of the cover page for each Reporting Person, respectively.

---

| | |
|:---|:---|
| **Item 2(d).** | **Title of Class of Securities:**  |

---

Common Shares, par value $0.0000000341740141 per share of the Issuer ("Common Shares").

---

| | |
|:---|:---|
| **Item 2(e).** | **CUSIP Number:**  |

---

G76279101

**Item 3.** **If this Statement is Filed Pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:** <br>

Not applicable.

**Item 4.** **Ownership.** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Amount beneficially owned: See Row 9 of the cover pages for each Reporting Person, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Percent of class: See Row 11 of the cover pages for each Reporting Person, respectively. Calculated using 725,418,787 Common Shares issued and outstanding as of November 10, 2022, as disclosed by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2022, as filed with the Securities and Exchange Commission on November 14, 2022.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: See Row 5 of the cover pages for each Reporting Person, respectively.

(ii) Shared power to vote or to direct the vote: See Row 6 of the cover pages for each Reporting Person, respectively.

(iii) Sole power to dispose or to direct the disposition of: See Row 7 of the cover pages for each Reporting Person, respectively.

(iv) Shared power to dispose or to direct the disposition of: See Row 8 of the cover pages for each Reporting Person, respectively.

Sumitomo Pharma directly owns the Common Shares. Sumitomo Pharma is a 51.78%-owned subsidiary of Sumitomo Chemical. Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined under Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the Common Shares that Sumitomo Pharma owns. Sumitomo Chemical disclaims beneficial ownership of such Common Shares except to the extent of its pecuniary interest therein.

**Item 5.** **Ownership of Five Percent or Less of Class.** <br>

Not applicable.

**Item 6.** **Ownership of More Than Five Percent on Behalf of Another Person.** <br>

Not applicable.

**Item 7.** **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.** <br>

Not applicable

**Item 8.** **Identification and Classification of Members of the Group.** <br>

Not applicable.

**Item 9.** **Notice of Dissolution of Group.** <br>

Not applicable.

**Item 10.** **Certifications.** <br>

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

------

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 3, 2023

---

| | |
|:---|:---|
| **Sumitomo Chemical Co., Ltd.** | **Sumitomo Chemical Co., Ltd.** |
| By: | /s/ Takeo Kitayama |
| Name: | Takeo Kitayama |
| Title: | Executive Officer, General Manager,<br> Corporate Planning Office |
| **Sumitomo Pharma Co., Ltd.** | **Sumitomo Pharma Co., Ltd.** |
| By: | /s/ Tsutomu Nakagawa |
| Name: | Tsutomu Nakagawa |
| Title: | Executive Officer, Senior Director<br> Global Corporate Strategy |

---

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| Exhibit Number | Title |
| 99.1 | Joint Filing Agreement |

---

## Exhibit 99.1

**EXHIBIT 99.1** 

JOINT FILING AGREEMENT

This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Shares, par value $0.0000000341740141 per share, of Roivant Sciences Ltd. (this "Agreement"), is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below that is named as a reporting person in such filing in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated: February 3, 2023

---

| | |
|:---|:---|
| **Sumitomo Chemical Co., Ltd.** | **Sumitomo Chemical Co., Ltd.** |
| By: | /s/ Takeo Kitayama |
| Name: | Takeo Kitayama |
| Title: | Executive Officer, General Manager, Corporate Planning Office |
| **Sumitomo Pharma Co., Ltd.** | **Sumitomo Pharma Co., Ltd.** |
| By: | /s/ Tsutomu Nakagawa |
| Name: | Tsutomu Nakagawa |
| Title: | Executive Officer, Senior Director,<br> Global Corporate Strategy |

---